Darusentan: Difference between revisions

Latest revision as of 16:00, 4 August 2024

Citable Version ^[?]

This editable Main Article is under development and subject to a disclaimer.

[edit intro]

darusentan

IUPAC name:	(2S)-2-(4,6-dimethoxypyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid
Synonyms:
Formula:	C₂₂H₂₂N₂O₆

Uses:

hypertension

Properties:

Hazards:

see side effects & drug interactions

Mass (g/mol):	CAS #:
410.41988	171714-84-4

In medicine, darusentan is a medication for treating hypertension that is a selective endothelin type A antagonist. It is a vasodilator.^[1]

Fluid retention is the most common drug toxicity.^[1]

↑ ^1.0 ^1.1 Weber MA et al. (2009) A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet DOI:10.1016/S0140-6736(09)61500-2

@@ Line 1: / Line 1: @@
+{{subpages}}
+{{Chem infobox
+|align=right
+|image=[[Image:Darusentan.png|center|thumb|300px]]
+|width=300px
+|molname= darusentan
+|synonyms=
+|molformula= C<sub>22</sub>H<sub>22</sub>N<sub>2</sub>O<sub>6</sub>
+|molmass= 410.41988
+|uses=hypertension
+|properties=
+|hazards=see side effects & drug interactions
+|iupac= (2S)-2-(4,6-dimethoxypyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic
+acid
+|casnumber= 171714-84-4
+}}
 In [[medicine]], '''darusentan''' is a [[medication]] for treating [[hypertension]] that is a selective endothelin type A antagonist. It is a vasodilator.<ref name="10.1016/S0140-6736(09)61500-2">Weber MA et al. (2009) A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet {{doi|10.1016/S0140-6736(09)61500-2}}</ref>
@@ Line 5: / Line 22: @@
 ==References==
-<references/>
+<references/>[[Category:Suggestion Bot Tag]]